Alpha-1 Antitrypsin Deficiency

Part of the debate – in Westminster Hall at 3:59 pm on 31st October 2018.

Alert me about debates like this

Photo of Jim Shannon Jim Shannon Shadow DUP Spokesperson (Human Rights), Shadow DUP Spokesperson (Health) 3:59 pm, 31st October 2018

I congratulate the hon. Gentleman on bringing this matter to Westminster Hall for consideration. As my party’s health spokesperson, this is something that I have responsibility for, so I appreciate it. While AATD can cause a lot of conditions, such as COPD or liver disease, it is a separate condition. If treatment for it was available in the UK, that could prevent the development of other lung and liver conditions, as he has said. Surely the prevention of other diseases would be of long-term benefit to the national health service. I say that to the Minister in particular. While there are some lifestyle changes that people can make, AATD is inherited and if a person has inherited two ZZ genotypes they are likely to develop further issues.

Does the hon. Gentleman agree that time must be given to clinical trials involving AAT augmentation therapy? If he does, perhaps the Minister would like to respond positively to that.